Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus ...

Financially, Creative Medical has limited cash reserves, high cash burn, and will likely need dilutive financing. Click here ...

Detailed price information for Ernexa Therapeutics Inc (ERNA-Q) from The Globe and Mail including charting and trades.

Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs ... Boral Capital LLC is an investment bank headquartered in New York which provides advisory and financing ...

Brian Culley; Chief Executive Officer, Director; Lineage Cell Therapeutics Inc Jill Howe; Chief Financial Officer; Lineage Cell Therapeutics Inc William Wood; Analyst; B. Riley Securities Jack Allen; ...

Patient dosing underway in CALiPSO-1 trial in the U.S.: In March 2025, the first patient was dosed in the Phase 1 CALiPSO-1 trial which is currently evaluating CNTY-101 as a potential treatment for ...

Universal Cells had developed a distinctive method of modifying pluripotent stem cells ... For each treatment, scientists can create a bank of universal donor cells, and a desired group of ...

The expansion of patient population and reach is well supported by the ability to produce FT819 in large quantities from a master cell bank, ensuring consistent ... Human induced pluripotent stem ...

The ability to reprogram mature, differentiated cells into induced pluripotent stem cells (iPSCs ... stock that can cover almost the entire Japanese population. iPSCs in this bank were obtained by the ...

Two small clinical trials tested the safety of injecting stem cells into the brains of Parkinson's patients and found no adverse effects ...